Eradication and follow-up of Helicobacter pylori infection in hemodialysis patients

被引:29
作者
de Bustillo, EM
Tomero, JAS
Sanz, JC
Moreno, JA
Jiménez, I
López-Brea, M
Pajares, JM
Traver, JA
机构
[1] Hosp Univ Princesa, Serv Nefrol, Dept Nephrol, E-28006 Madrid, Spain
[2] Hosp Univ Princesa, Dept Microbiol, E-28006 Madrid, Spain
[3] Hosp Univ Princesa, Dept Gastroenterol, E-28006 Madrid, Spain
关键词
hemodialysis; Helicobacter pylori; C-13 Urea Breath Test; eradication therapy;
D O I
10.1159/000044992
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
It is currently accepted that Helicobacter pylori (Hp) infection is crucial in the pathogenesis of peptic ulcer. Therefore, we developed a prospective study to assess the prevalence of Hp infection by the C-13 Urea Breath Test (C-13 UBT) in 52 hemodialysis patients, and we evaluated the efficacy of two consecutive eradication regimens in 23 positive patients with dyspepsia and/or on a transplantation list. The correlation between anti-Hp serology and C-13 UBT results was also analyzed in 34 patients who were followed up during 18 months. The Hp prevalence by C-13 UBT was 63.5% (33/52). The eradication rate after the first cycle of therapy (amoxicillin 500 mg/8 h and omeprazole 20 mg/12 h, 14 days) was 60.8% (14/23). After the second cycle (clarithromycin 500 mg/12 h plus omeprazole 20 mg/12 h, 14 days), the eradication rate reached 82.6% (19/23). The serological procedure showed a good correlation with C-13 UBT (about 80% sensitive and specific) when very restrictive diagnostic and eradication criteria were adopted. We conclude that an eradication rate higher than 80% can be reached after two consecutive cycles of dual therapy in hemodialysis patients. Anti-Hp serological. tests must be cautiously interpreted in these patients.
引用
收藏
页码:55 / 60
页数:6
相关论文
共 26 条
[1]  
ALCALDE M, 1994, MED CLIN-BARCELONA, V103, P371
[2]  
DEBOER WA, 1995, GASTROENTEROLOGY, V109, P327
[3]   MULTILABORATORY COMPARISON OF 8 COMMERCIALLY AVAILABLE HELICOBACTER-PYLORI SEROLOGY KITS [J].
FELDMAN, RA ;
DEEKS, JJ ;
EVANS, SJW .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1995, 14 (05) :428-433
[4]   PHARMACOKINETIC OPTIMIZATION OF THE TREATMENT OF PEPTIC-ULCER IN PATIENTS WITH RENAL-FAILURE [J].
GLADZIWA, U ;
KLOTZ, U .
CLINICAL PHARMACOKINETICS, 1994, 27 (05) :393-408
[5]  
GLADZIWA U, 1993, NEPHROL DIAL TRANSPL, V8, P301
[6]   EFFECT OF ANTIMICROBIAL THERAPY ON THE SPECIFIC SEROLOGICAL RESPONSE TO HELICOBACTER-PYLORI INFECTION [J].
GLUPCZYNSKI, Y ;
BURETTE, A ;
GOOSSENS, H ;
DEPREZ, C ;
BUTZLER, JP .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1992, 11 (07) :583-588
[7]   EVALUATION OF A COMMERCIALLY AVAILABLE COMPLEMENT-FIXATION TEST FOR DIAGNOSIS OF HELICOBACTER-PYLORI INFECTION AND FOR FOLLOW-UP AFTER ANTIMICROBIAL THERAPY [J].
GOOSSENS, H ;
GLUPCZYNSKI, Y ;
BURETTE, A ;
VANDENBORRE, C ;
DEPREZ, C ;
BODENMANN, J ;
KELLER, A ;
BUTZLER, JP .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (12) :3230-3233
[8]   EVALUATION OF A COMMERCIALLY AVAILABLE 2ND-GENERATION IMMUNOGLOBULIN-G ENZYME-IMMUNOASSAY FOR DETECTION OF HELICOBACTER-PYLORI INFECTION [J].
GOOSSENS, H ;
GLUPCZYNSKI, Y ;
BURETTE, A ;
VANDENBORRE, C ;
BUTZLER, JP .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (01) :176-180
[9]   Helicobacter pylori in kidney allograft recipients: High prevalence of colonization and low incidence of active inflammatory lesions [J].
Hruby, Z ;
MyszkaBijak, K ;
Gosciniak, G ;
Blaszczuk, J ;
Czyz, W ;
Kowalski, P ;
Falkiewicz, K ;
Szymanska, G ;
PrzondoMordarska, A .
NEPHRON, 1997, 75 (01) :25-29
[10]   SIGNIFICANTLY LOWER PREVALENCE OF HELICOBACTER-PYLORI IN UREMIC PATIENTS THAN IN PATIENTS WITH NORMAL RENAL-FUNCTION [J].
JASPERSEN, D ;
FASSBINDER, W ;
HEINKELE, P ;
KRONSBEIN, H ;
SCHORR, W ;
RASCHKA, C ;
BRENNENSTUHL, M .
JOURNAL OF GASTROENTEROLOGY, 1995, 30 (05) :585-588